Funding for this research was provided by:
Received: 5 June 2020
Accepted: 10 September 2020
First Online: 7 October 2020
Ethics approval and consent to participate
: Each stage of the study was reviewed and approved by an independent ethics board (APPEAL-1: Freiburger Ethik-Kommission International; APPEAL-2: Western Independent Review Board). Participants were provided with information about the study and gave informed consent prior to taking part in either stage.
: Not applicable.
: PC and BH are members of Team APPEAL and their patient advocacy organisations have received honoraria from Aimmune Therapeutics. GP is a member of Team APPEAL and has received honoraria from Aimmune Therapeutics for advice; honoraria from Bausch + Lomb for advice; honoraria from Mylan and Novartis; and research funding from Stallergènes and ALK-Abello. AV and RM are employees of Aimmune Therapeutics. SA and KG report consulting for Aimmune Therapeutics. RP reports consulting for Aimmune Therapeutics.